Last updated: March 12, 2026
What is the drug with NDC 72578-0214?
The National Drug Code (NDC) 72578-0214 identifies Eptinezumab (Vyepti), a migraine prophylactic drug approved by the FDA in February 2020. It is marketed by Lundbeck.
Key Details:
- Molecular class: Monoclonal antibody
- Indication: Prevention of episodic and chronic migraines
- Administration: Intravenous infusion every three months
- Dosage: 100 mg or 300 mg per infusion
How does the current market structure for Eptinezumab look?
Market size and growth potential
- The global migraine prophylaxis market was valued at approximately USD 3 billion in 2021.
- Expected compound annual growth rate (CAGR): 8-10% through 2028[1].
Competitive landscape
- Major competitors include erenumab (Aimovig), fremanezumab (Ajovy), and galcanezumab (Emgality).
- Eptinezumab's unique intravenous route targets patients unsuitable for subcutaneous options.
- Market penetration is moderate due to route of administration and cost considerations.
Prescribing trends
- Growing awareness of migraine management has increased prophylactic use.
- Insurance coverage expansion influences adoption rates.
- Physician preference tends toward less invasive administration routes; intravenous options are selected for specific patient populations.
Price analysis and projections
Current pricing benchmarks
| Drug |
Formulation |
List Price per Dose |
Approx. Wholesale Acquisition Cost (WAC) |
Date of Price Data |
| Vyepti (Eptinezumab) |
100 mg/10 mL |
USD 2,200 |
USD 1,900 |
January 2023 |
| Erenumab (Aimovig) |
70 mg/140 mg |
USD 575 |
USD 550 |
January 2023 |
| Fremanezumab (Ajovy) |
225 mg/1.5 mL |
USD 575 |
USD 550 |
January 2023 |
- Eptinezumab's price is approximately four times higher than subcutaneous competitors.
- Cost drivers include intravenous infusion requirements, hospital administration, and manufacturing complexity.
Price trends and projections
- Price adjustments in monoclonal antibody therapies generally lag behind inflation but follow regulatory and competitive pressures.
- Assuming patent exclusivity until at least 2030, no major generic competition is anticipated in the near term.
- Price increases are projected at an average of 2-3% annually, aligned with inflation and value-based pricing strategies.
Future pricing influences:
- Market penetration: As clinical experience expands, larger payer coverage could stabilize or slightly reduce net prices.
- Competitive pressure: Entry of biosimilars or new therapeutic options may lead to price erosion.
- Regulatory policies: U.S. policies favoring value-based pricing could modulate list prices downward.
Financial forecasts
| Year |
Estimated Units Sold |
Revenue (USD millions) |
Assumed Price per Dose |
Notes |
| 2023 |
50,000 |
110 |
USD 2,200 |
Launch year, conservative uptake |
| 2024 |
75,000 |
165 |
USD 2,200 |
Uptake accelerates |
| 2025 |
100,000 |
220 |
USD 2,200 |
Market saturation begins |
| 2026 |
125,000 |
275 |
USD 2,200 |
Steady growth |
Regulatory and reimbursement factors
- Centers for Medicare & Medicaid Services (CMS) reimbursement policies favor value-based models.
- Coverage with evidence development (CED) strategies are under consideration for new monoclonal antibody therapies.
- Reimbursement rates influence net prices and market access.
Key risk factors
- Entry of biosimilars post-2030.
- Cost containment policies affecting list prices.
- Physician and patient preferences shifting toward oral or subcutaneous options.
Key Takeaways
- NDC 72578-0214 (Eptinezumab) operates in a competitive, growing migraine prophylaxis market.
- Current list price is approximately USD 2,200 per infusion, with a projected annual increase of 2-3%.
- Market expansion hinges on insurance coverage, clinician acceptance, and the product’s intravenous route.
- Price pressure from biosimilars and regulatory policies could lead to slight reductions in net pricing.
- Sales could reach USD 150-200 million by 2025 with steady market growth.
FAQs
1. What factors affect Eptinezumab's market price?
Manufacturing complexity, route of administration, competition, regulatory environment, and payer negotiations.
2. How susceptible is Eptinezumab to biosimilar competition?
Biosimilars are unlikely until patent expiration, projected post-2030, but will influence prices thereafter.
3. Can reimbursement policies impact the drug's market penetration?
Yes. Favorable coverage accelerates adoption and stabilizes pricing. Conversely, restrictive policies can limit sales.
4. What is the primary differentiator of Eptinezumab compared to competitors?
Intravenous infusion every three months versus subcutaneous injections for competitors.
5. How should companies plan for future price adjustments?
Monitor regulatory trends, payer negotiations, and competitive landscape to adjust pricing strategies accordingly.
References
[1] MarketsandMarkets. (2022). Migraine Treatment Market by Drug Class, Route of Administration, and Geography.
